Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

A synthetic recombinant PRP is the next phase of our strategic plan in building a new therapeutic drug class aimed at treating a range of chronic diseases

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.